Moretta Lorenzo
Department of Experimental Medicine, Giannina Gaslini Institute, University of Genova, Center of Excellence for Biomedical Research, Genova, Italy.
Surg Oncol. 2007 Dec;16 Suppl 1:S3-5. doi: 10.1016/j.suronc.2007.10.043. Epub 2007 Nov 26.
The past fifteen years have witnessed great progress in our undestanding of how natural killer (NK) cells function, their role in innate defenses and their possible exploitation in therapy. This contribution traces the major advances in these formerly mysterious cells, from the first discovery of HLA-class I-specific inhibitory receptors to a more recent major breakgthrough that highlighted important perspectives and major expectations regarding the cure of life-threatening leukemias. The key role of "alloreactive" NK cells in eradicating acute myeloid leukemias and in preventing both graft rejection and graft-versus-host disease, led to a true revolution in bone marrow transplantation. Thus, it is now possible to search for appropriate HLA class I mismatches to set NK cells in action to cure high risk leukemias.
在过去的十五年里,我们对自然杀伤(NK)细胞的功能、它们在先天防御中的作用以及它们在治疗中可能的应用的理解取得了巨大进展。本文追溯了这些曾经神秘的细胞的主要进展,从首次发现HLA-I类特异性抑制性受体到最近的一项重大突破,该突破突出了关于治愈危及生命的白血病的重要观点和主要期望。“同种异体反应性”NK细胞在根除急性髓系白血病以及预防移植排斥和移植物抗宿主病方面的关键作用,引发了骨髓移植领域的一场真正革命。因此,现在有可能寻找合适的HLA-I类错配,以使NK细胞发挥作用来治愈高危白血病。
Surg Oncol. 2007-12
Trends Immunol. 2002-9
Ann Rheum Dis. 2008-12
Cell Mol Immunol. 2004-2
J Innate Immun. 2011-3-12
Best Pract Res Clin Haematol. 2006
Biol Proced Online. 2025-8-9
Clin Exp Metastasis. 2013-10